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Introduction
Regular moderate exercise and its beneficial influence on
health have already been well-investigated. However,
information on high volume exercise which might lead to
increased oxidative stress and DNA damage is still very
limited. The purpose of the present study was to investi-
gate the effect of an Ironman triathlon race (3.8 km swim,
180 km cycle, 42 km run) on genomic stability and a pos-
sible DNA damage.
Materials and methods
The sister chromatid exchange (SCE) assay is a cytogenic
biomarker, which can be influenced by various factors
such as oxidative stress that occurs during extreme endur-
ance exercise. Within this study SCEs and high frequency
cells (HFCs) were measured in peripheral blood lym-
phocytes of nine well trained male triathletes (age 38 ± 6
years; VO2 peak 55.59 ± 2.97 ml/kg/min; height 179.1 ±
4.19 cm; weight 76.3 ± 4.27 kg). Blood samples were col-
lected 48 h before and 24 h post race.
Results
The mean SCE frequency in the Ironman triathletes 2 days
before the race was 6.55 ± 2.71 per metaphase, which was
significantly higher than post race (5.69 ± 2.60 SCEs per
metaphase, p < 0.05). Additionally the mean of HFCs sig-
nificantly decreased from 11.06 ± 2.66 per metaphase
before the race to 9.42 ± 3.74 per metaphase post race (p
< 0.05).
Conclusion
The significant decrease of SCEs and HFCs after the Iron-
man triathlon race provides an indication of endogenous
repair mechanisms or counterregulations, which seem to
prevent DNA damages probably through releasing anti-
oxidants.
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